Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/171561
Title: | Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients |
Author: | Cuyàs, Elisabet Fernández Arroyo, Salvador Buxó, Maria Pernas, Sònia Dorca, Joan Álvarez, Isabel Martínez, Susana Pérez García, José Manuel Batista López, Norberto Rodríguez Sánchez, César A. Amillano, Kepa Domínguez, Severina Luque, Maria Morilla, Idoia Stradella, Agostina Viñas, Gemma Cortés, Javier Verdura, Sara Brunet, Joan López Bonet, Eugeni Garcia, Margarita Saidani, Samiha Joven, Jorge Martin Castillo, Begoña Menendez, Javier A. |
Keywords: | Càncer de mama Nutrició Breast cancer Nutrition |
Issue Date: | 15-Jan-2019 |
Publisher: | Impact Journals |
Abstract: | Certain dietary interventions might improve the therapeutic index of cancer treatments. An alternative to the "drug plus diet" approach is the pharmacological reproduction of the metabolic traits of such diets. Here we explored the impact of adding metformin to an established therapeutic regimen on the systemic host metabolism of cancer patients. A panel of 11 serum metabolites including markers of mitochondria! function and intermediates/products of folate-dependent one-carbon metabolism were measured in paired baseline and post-treatment sera obtained from HER2-positive breast cancer patients randomized to receive either metformin combined with neoadjuvant chemotherapy and trastuzumab or an equivalent regimen without metformin. Metabolite profiles revealed a significant increase of the ketone body beta-hydroxybutyrate and of the TCA intermediate alpha-ketoglutarate in the metformin-containing arm. A significant relationship was found between the follow-up levels of homocysteine and the ability of treatment arms to achieve a pathological complete response (pCR). In the metformin-containing arm, patients with significant elevations of homocysteine tended to have a higher probability of pCR. The addition of metformin to an established anticancer therapeutic regimen causes a fasting-mimicking modification of systemic host metabolism. Circulating homocysteine could be explored as a clinical pharmacodynamic biomarker linking the antifolate-like activity of metformin and biological tumor response. |
Note: | Reproducció del document publicat a: https://doi.org/10.18632/aging.101960 |
It is part of: | Aging-us, 2019, vol. 11, num. 9, p. 2874-2888 |
URI: | http://hdl.handle.net/2445/171561 |
Related resource: | https://doi.org/10.18632/aging.101960 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
CuyasE.pdf | 2.02 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License